Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

← catalyst calendar

NCT03345823 · readout ≤ 407 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
747estimated
Sites
466
Countries
Argentina, Australia, Austria +46

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2018-03-21actualWhen the study began enrolling
Primary completionSep 2027estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionSep 2027estimatedThe whole study's end, after follow-up
First posted2017-11-17actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-04-09actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Crohn's Disease

Interventions

  • Drug: Upadacitinib — also filed as ABT-494, RINVOQ
  • Drug: Placebo for Upadacitinib

Primary outcomes

what the primary-completion date above is the date OF
Sub-Study 1: Percentage of Participants with Clinical Remission per Crohn's Disease Activity Index (CDAI)
measured Week 52
Sub-Study 1: Percentage of Participants with Endoscopic Response
measured Week 52
Number of Participants with Adverse Events
measured Through Week 240

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed